Principal Financial Group
DFTX

Principal Financial Group’s Definium Therapeutics DFTX Stock Holding History

Principal Financial Group’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-3,899
Closed -$65K – 2600
2022
Q1 		$65K Sell
3,899
-47
-1% -$815 ﹤0.01% 2473
2021
Q4 		$82K Sell
3,946
-921
-19% -$29.4K ﹤0.01% 2455
2021
Q3 		$170K Buy
4,867
+1,434
+42% +$62K ﹤0.01% 2451
2021
Q2 		$178K Buy
+3,433
New +$180K ﹤0.01% 2485

Other funds holding DFTX

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Swiss National Bank
Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Principal Financial Group's DFTX Position: Q2 2022 in Review

Principal Financial Group sold out of Definium Therapeutics (DFTX) in Q2 2022, closing a stake of 3,899 shares — an estimated $65K sold.

Principal Financial Group first reported a position in DFTX in Q2 2021 and held it in 4 quarters. The position peaked at $178K in Q2 2021. 155 funds tracked by Wall St. Rank hold DFTX as of Q2 2022.

  • Principal Financial Group reported no remaining Definium Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Principal Financial Group sold 3,899 Definium Therapeutics shares in Q2 2022, an estimated $65K.
  • Principal Financial Group first reported a position in Definium Therapeutics in Q2 2021 and held it in 4 quarters.
  • Principal Financial Group's Definium Therapeutics position peaked at $178K in Q2 2021.
  • 155 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2022.

Based on Principal Financial Group's 13F filing for Q2 2022, filed 10 Aug 2022.